Brixadi® is a prescription medication used to treat adults with moderate to severe OUD. Brixadi® contains the active ingredient buprenorphine, a well-established treatment for OUD. Brixadi® helps to mitigate opioid cravings without eliciting a “high” and, over time, can help decrease a patient's reliance on opioids.

This medication is administered as a subcutaneous injection by a healthcare professional. It is part of a comprehensive treatment plan for OUD that includes counseling and psychosocial support.

How Does Brixadi® Work?

Brixadi® is used in the treatment of opioid dependence. Buprenorphine, the active ingredient, is a partial opioid agonist. It works by binding to the same receptors in the brain that opioids bind to, but it produces less euphoria and physical dependence.

This helps to reduce cravings and withdrawal symptoms, allowing individuals to stabilize their opioid use and focus on recovery. Brixadi® is administered as a once-monthly injection, providing sustained levels of buprenorphine in the body to support long-term treatment adherence and recovery.

Brixadi® vs. Other Medications

Brixadi® is a once-monthly injectable form of buprenorphine and offers advantages over other medication-assisted treatment (MAT) options for opioid dependence.

Compared to daily oral medications like buprenorphine/naloxone (Suboxone®) or methadone, Brixadi® provides consistent blood levels, reducing the need for daily dosing and the potential for misuse or diversion. Additionally, Brixadi® eliminates the need for daily self-administration, improving treatment adherence and reducing the risk of relapse.

Other MAT options like Suboxone® and methadone also have their own benefits and considerations, and the choice of treatment should be tailored to individual needs and preferences in consultation with a healthcare provider.